– Reuters Citing Investor Day
AIM ImmunoTech Announces Abstract Accepted For Poster Presentation At British Society For Immunology Congress 2022 Dec. 7
Poster No: P-220
Title: Safety, tolerability and biological activity of repeated intranasal administration of TLR3 agonist Ampligen (Poly I:Poly C12U) in healthy subjects
Presenter: Lisanne C.A. Smidt -